CLINICAL ROLE -
Approaching Ethical Dilemmas in Oncology Pharmacy
Karen Fancher, PharmD, BCOP, discusses some guiding principles for oncology pharmacists when facing ethical dilemmas and provides some recommendations for navigating those challenges.
Watch
Study Suggests Patients With Low-Risk CLL May Stop Specialized Follow-Up Visits
The results demonstrated similar overall survival between patients with chronic lymphocytic leukemia who discontinued specialized follow-ups versus those who continued.
Read More
The Importance of Hemoglobin A1c Management in Type 2 Diabetes
Pharmacists can help to interpret HbA1c and glucose results when patients come to pick up medications and contact prescribers and/or make recommendations based off patient results.
Psychedelic Medicine Could Fill Care Gap in Psychiatric Care
However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.
FDA Approves Cilta-Cel for Treatment of Relapsed, Refractory Multiple Myeloma
The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.
Venetoclax With 5-Azacytidine Effective in Treating Patients With Multiple Myeloma
Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.
Biosimilars in Retina Space Expected to Grow in 2024, Coming Years
In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.
Study: Inappropriate Diagnosis of Community-Acquired Pneumonia is Common
Investigators found that older adults, adults with dementia, and adults with altered mental status were more likely to be inappropriately diagnosed with CAP when hospitalized.
Digital Therapeutics Might Address Gaps in Care for Mental Health Patients
Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.
Understanding Social Determinants of Health and Their Impact on Mental Illness Treatment
Pharmacists can address social determinants to improve patient well-being and treatment.
Managing Insomnia in Special Populations and Treatment-Resistant Cases
Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.
Anticholinergic Medications in Older Adults and Strategies for Safe Deprescribing
Linking strong anticholinergic medications to increased risk of dementia in older adults
Pharmacists Improve Quality of Depression Care at Patient, Community Levels
Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.
Investigators Find Piezo1 Has Potential for the Future of Asthma Treatment
Piezo1 is a protein produced by type 2 innate lymphoid cells when activated by an allergen and can limit the immune cell’s activity when triggered by a reaction.
Newest Indication for Bempedoic Acid Expands Patient Population
In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.
Expert: New Schizophrenia Treatments Targeting Muscarinic Receptors
Potential for integration into care and future advancements for gaps in current schizophrenia treatments
More Research Needed for Treatment of Clozapine-Resistant Schizophrenia
Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.
Contraceptive Considerations and Communication Strategies for Patients with Psychiatric Conditions
Guidance on evaluating contraceptive options for patients with psychiatric conditions
Patient Preferences Play Essential Part in Contraceptive Care
Although there are medical considerations for patients with psychiatric conditions, prescribers must consider patient preference to increase adherence and effectiveness of contraception.
FDA Approves Dolutegravir/Lamivudine for Treatment of Adolescents With HIV-1 Infection
The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.
Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure
The finding did not reach statistical significance in the primary composite endpoint.
Novel Approaches to Treating the Full Spectrum of Schizophrenia Symptoms, Modulating Dopamine and Glutamate Neurotransmission
New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.
Study: Blended Antioxidant Supplement Could Improve Age-Related Health Decline
Aged mice displayed improvements in their spatial cognition, short-term memory, and muscle durability.
Safety Data Confirm Viability of Flu, RSV Vaccines For Patients at Risk of Heart Failure
Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.
Pharmacists Facilitate Harm Reduction for Patients With Anxiety Using Cannabis
Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.
Expert: The Evolving Landscape of Pharmacologic Research and Clinical Management of Symptoms in Borderline Personality Disorder
Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder
Exploring Treatment Options for Patients with Treatment-Resistant Schizophrenia
Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia
New Data Shows Positive Results for Sotagliflozin for Patients With Chronic Kidney Disease, Diabetes
The abstracts will be presented at the American College of Cardiology Conference from April 6 to April 8, 2024, in Atlanta, Georgia.
Novel Drugs Targeting Different Pathways Show Promise in Schizophrenia
Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.
Study: Empagliflozin Reduces MACE Regardless of Baseline Albuminuria Levels
The results further confirm earlier findings from the EMPA-KIDNEY trial.